IMUX Stock Forecast 2025-2026
Distance to IMUX Price Targets
IMUX Price Momentum
🤔 Considering Immunic (IMUX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest IMUX Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, IMUX has a bullish consensus with a median price target of $11.50 (ranging from $5.00 to $28.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $1.15, the median forecast implies a 900.0% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 2,334.8% upside. Conversely, the most conservative target is provided by Faisal Khurshid at Leerink Partners, suggesting a 334.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IMUX Analyst Ratings
IMUX Price Target Range
Latest IMUX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IMUX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 26, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $17.00 |
| Feb 21, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $10.00 |
| Feb 20, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $17.00 |
| Jan 7, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $17.00 |
| Nov 25, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Initiates | $10.00 |
| Nov 7, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $17.00 |
| Oct 22, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $17.00 |
| Sep 18, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $17.00 |
| Sep 16, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $17.00 |
| Sep 9, 2024 | Leerink Partners | Faisal Khurshid | Outperform | Assumes | $5.00 |
| Aug 27, 2024 | B. Riley Securities | William Woods | Buy | Initiates | $6.00 |
| Jul 16, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Reiterates | $28.00 |
| Apr 5, 2024 | Brookline Capital | Tyler Bussian | Buy | Initiates | $10.00 |
| Oct 10, 2023 | Wedbush | Andreas Argyrides | Outperform | Maintains | $7.00 |
| Jul 27, 2023 | Wedbush | Andreas Argyrides | Outperform | Reiterates | $5.00 |
| Jan 31, 2023 | Wedbush | Andreas Argyrides | Outperform | Assumes | $5.00 |
| Oct 21, 2022 | SVB Leerink | Thomas Smith | Market Perform | Downgrade | $5.00 |
| Sep 19, 2022 | HC Wainwright & Co. | Gobind Singh | Buy | Assumes | $26.00 |
| Aug 8, 2022 | Aegis Capital | Nathan Weinstein | Buy | Maintains | $35.00 |
| Jun 3, 2022 | SVB Leerink | Thomas Smith | Outperform | Maintains | $9.00 |
Immunic Inc. (IMUX) Competitors
The following stocks are similar to Immunic based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Immunic Inc. (IMUX) Financial Data
Immunic Inc. has a market capitalization of $103.59M with a P/E ratio of -0.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -216.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Immunic Inc. (IMUX) Business Model
About Immunic Inc.
Develops therapies for autoimmune and inflammatory diseases.
Immunic Inc. generates revenue by developing and advancing oral therapies aimed at treating severe and chronic autoimmune and inflammatory diseases. The company focuses on creating drug candidates that inhibit specific proteins involved in inflammatory pathways, targeting conditions such as multiple sclerosis, ulcerative colitis, and Crohn's disease.
Immunic plays a significant role in the biotechnology sector, addressing unmet medical needs and contributing to advancements in healthcare. The company is aligned with the industry trend towards personalized medicine and targeted therapies, enhancing its relevance in modern medical treatment.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
85
CEO
Dr. Daniel Vitt Ph.D.
Country
United States
IPO Year
N/A
Website
imux.comImmunic Inc. (IMUX) Latest News & Analysis
Immunic, Inc. (Nasdaq: IMUX) will present two abstracts at the 34th Annual Meeting of the Society for Virology in Hamburg, Germany, from March 4-7, 2025.
Immunic's participation in key scientific conferences and presentation of accepted abstracts can enhance its visibility, attract potential investors, and signal progress in its drug development pipeline.
The weight loss drug market, driven by GLP-1 agonists, is expected to reach $130 billion by 2030, prompting pharmaceutical and biotech firms to develop oral treatments.
The projected $130 billion weight loss drug market indicates a lucrative opportunity for pharmaceutical companies, potentially driving stock prices and attracting investment in the sector.
Immunic Inc (NASDAQ:IMUX) will present key data on its drug vidofludimus calcium at the ACTRIMS Forum 2025, highlighting its potential as a new multiple sclerosis treatment.
Immunic's presentation of vidofludimus calcium at a major MS forum signals potential advancements in treatment, which could enhance its market position and attract investor interest.
Immunic, Inc. (Nasdaq: IMUX) presented data on vidofludimus calcium at ACTRIMS Forum 2025. Top-line results from the Phase 2 CALLIPER trial in progressive MS are expected in April.
Positive preclinical data and upcoming Phase 2 trial results for vidofludimus calcium may indicate a promising treatment for multiple sclerosis, potentially boosting Immunic, Inc.'s stock value.
Immunic Inc (NASDAQ:IMUX) announced that its drug candidate IMU-856, initially for celiac disease, shows potential for obesity treatment by significantly increasing GLP-1 levels.
Immunic's drug IMU-856 shows promise for obesity treatment by boosting GLP-1 levels, potentially expanding its market and driving stock value through increased investor interest.
Immunic Inc (NASDAQ:IMUX) announced new data showing that its oral therapy IMU-856 could aid weight management by increasing GLP-1 levels, based on a phase 1b trial analysis.
Immunic Inc's positive data on IMU-856 for weight management could signal a new revenue stream, enhancing its market valuation and attracting investor interest in the biotech sector.
Frequently Asked Questions About IMUX Stock
What is Immunic Inc.'s (IMUX) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Immunic Inc. (IMUX) has a median price target of $11.50. The highest price target is $28.00 and the lowest is $5.00.
Is IMUX stock a good investment in 2025?
According to current analyst ratings, IMUX has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.15. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IMUX stock?
Wall Street analysts predict IMUX stock could reach $11.50 in the next 12 months. This represents a 900.0% increase from the current price of $1.15. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Immunic Inc.'s business model?
Immunic Inc. generates revenue by developing and advancing oral therapies aimed at treating severe and chronic autoimmune and inflammatory diseases. The company focuses on creating drug candidates that inhibit specific proteins involved in inflammatory pathways, targeting conditions such as multiple sclerosis, ulcerative colitis, and Crohn's disease.
What is the highest forecasted price for IMUX Immunic Inc.?
The highest price target for IMUX is $28.00 from Yasmeen Rahimi at Piper Sandler, which represents a 2,334.8% increase from the current price of $1.15.
What is the lowest forecasted price for IMUX Immunic Inc.?
The lowest price target for IMUX is $5.00 from Faisal Khurshid at Leerink Partners, which represents a 334.8% increase from the current price of $1.15.
What is the overall IMUX consensus from analysts for Immunic Inc.?
The overall analyst consensus for IMUX is bullish. Out of 12 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.50.
How accurate are IMUX stock price projections?
Stock price projections, including those for Immunic Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
